Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.

BenzingaAug 7 08:28 ET

Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate

BenzingaAug 6 16:15 ET

WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research

Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.

wallstreetcnJul 29 23:40 ET

B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5

BenzingaJul 9 13:20 ET

Zai Lab Analyst Ratings

BenzingaJun 25 10:56 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET